Characterisation of the immune response to type I collagen in scleroderma

Arthritis Research and Therapy

Volumn 8, Issue 4, 2006, Pages

  Warrington, Kenneth J ^a   Nair, Usha ^a   Carbone, Laura D ^a,b   Kang, Andrew H ^a,b,c   Postlethwaite, Arnold E ^a,b  

^a Department of Medicine   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5-(6)-CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; ANTIBODY; COLLAGEN TYPE 1; CYTOKINE; FLUORESCEIN DERIVATIVE; FLUORESCENT DYE; SUCCINIMIDE DERIVATIVE;

AGED; BLOOD; CD4+ T LYMPHOCYTE; CELL DIVISION; CELL LINE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; SYSTEMIC SCLEROSIS; TH1 CELL; TH2 CELL;

AGED; ANTIBODIES; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CELL LINE; COLLAGEN TYPE I; CYTOKINES; FEMALE; FLOW CYTOMETRY; FLUORESCEINS; FLUORESCENT DYES; HUMANS; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SUCCINIMIDES; TH1 CELLS; TH2 CELLS;

EID: 34347238312     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2025     Document Type: Article

References (45)

1. Seyer JM, Kang AH, Rodnan G: Investigation of type I and type III collagens of the lung in progressive systemic sclerosis. Arthritis Rheum 1981, 24:625-631.
2. White B: Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am 1996, 22:695-708.
3. Fiocco U, Rosada M, Cozzi L, Ortolani C, De Silvestro G, Ruffatti A, Cozzi E, Gallo C, Todesco S: Early phenotypic activation of circulating helper memory T cells in scleroderma: Correlation with disease activity. Ann Rheum Dis 1993, 52:272-277.
4. Freundlich B, Jimenez SA: Phenotype of peripheral blood lymphocytes in patients with progressive systemic sclerosis: Activated T lymphocytes and the effect of D-penicillamine therapy. Clin Exp Immunol 1987, 69:375-384.
5. Steen VD, Engel EE, Charley MR, Medsger TA Jr: Soluble serum interleukin 2 receptors in patients with systemic sclerosis. J Rheumatol 1996, 23:646-649.
6. Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P: Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992, 166:255-263.
7. Fleischmajer R, Perlish JS, Reeves JR: Cellular infiltrates in scleroderma skin. Arthritis Rheum 1977, 20:975-984.
8. Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP: Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 1984, 27:645-653.
9. Wells AU, Lorimer S, Majumdar S, Harrison NK, Corrin B, Black CM, Jeffery PK, du Bois RM: Fibrosing alveolitis in systemic sclerosis: increase in memory T-cells in lung interstitium. Eur Respir J 1995, 8:266-271.
10. Sakkas LI, Platsoucas CD: Is systemic sclerosis an antigendriven T cell disease? Arthritis Rheum 2004, 50:1721-1733.
11. Sakkas LI, Xu B, Artlett CM, Lu S, Jimenez SA, Platsoucas CD: Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002, 168:3649-3659.
12. Stuart JM, Postlethwaite AE, Kang AH: Evidence for cell-mediated immunity to collagen in progressive systemic sclerosis. J Lab Clin Med 1976, 88:601-607.
13. Gurram M, Pahwa S, Frieri M: Augmented interleukin-6 secretion in collagen-stimulated peripheral blood mononuclear cells from patients with systemic sclerosis. Ann Allergy 1994, 73:493-496.
14. Hawrylko E, Spertus A, Mele CA, Oster N, Frieri M: Increased interleukin-2 production in response to human type I collagen stimulation in patients with systemic sclerosis. Arthritis Rheum 1991, 34:580-587.
15. McKown KM, Carbone LD, Bustillo J, Seyer JM, Kang AH, Postlethwaite AE: Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen Arthritis Rheum 2000, 43:1054-1061.
16. Huffstutter JE, DeLustro FA, LeRoy EC: Cellular immunity to collagen and laminin in scleroderma. Arthritis Rheum 1985, 28 775-780.
17. Turcanu V, Maleki SJ, Lack G: Characterization of lymphocyte responses to peanuts in normal children, peanut-allergic children, and allergic children who acquired tolerance to peanuts. J Clin Invest 2003, 111:1065-1072.
18. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980, 23:581-590.
19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
20. Seyer JM, Hutcheson ET, Kang AH: Collagen polymorphism in normal and cirrhotic human liver. J Clin Invest 1977, 59:241-248.
21. Rogge L, Papi A, Presky DH, Biffi M, Minetti LJ, Miotto D, Agostini C, Semenzato G, Fabbri LM, Sinigaglia F: Antibodies to the IL-12 receptor beta 2 chain mark human Th1 but not Th2 cells in vitro and in vivo. J Immunol 1999, 162:3926-3932.
22. Lyons AB, Parish CR: Determination of lymphocyte division by flow cytometry. J Immunol Methods 1994, 171:131-137.
23. Miller EJ: Chemistry of the collagens and their distribution. In Extracellular Matrix Biochemistry Edited by: Piez KA, Reddi AH. New York: Elsevier; 1984:41-82.
24. Kravis TC, Ahmed A, Brown TE, Fulmer JD, Crystal RG: Pathogenic mechanisms in pulmonary fibrosis: Collagen-induced migration inhibition factor production and cytotoxicity mediated by lymphocytes. J Clin Invest 1976, 58:1223-1232.
25. Schrier DJ, Phan SH, Ward PA: Cellular sensitivity to collagen in bleomycin-treated rats. J Immunol 1982, 129:2156-2159.
26. Tan FK, Arnett FC, Antohi S, Saito S, Mirarchi A, Spiera H, Sasaki T, Shoichi O, Takeuchi K, Pandey JP, et al.: Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. J Immunol 1999, 163:1066-1072.
27. Daskalova M, Taskov H, Dimitrova E, Baydanoff S: Humoral and cellular immune response to elastin in patients with systemic sclerosis. Autoimmunity 1997, 25:233-241.
28. Rao WH, Hales JM, Camp RD: Potent costimulation of effector T lymphocytes by human collagen type I. J Immunol 2000, 165 4935-4940.
29. Latham KA, Whittington KB, Zhou R, Qian Z, Rosloniec EF: Ex vivo characterization of the autoimmune T cell response in the HLA-DR1 mouse model of collagen-induced arthritis reveals long-term activation of type II collagen-specific cells and their presence in arthritic joints. J Immunol 2005, 174:3978-3985.
30. - costimulation-independent T cells in multiple sclerosis. J Clin Invest 2001, 108:1185-1194.
31. - T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity J Clin Invest 1996, 97:2027-2037.
32. Vallejo AN, Brandes JC, Weyand CM, Goronzy JJ: Modulation of CD28 expression: Distinct regulatory pathways during activation and replicative senescence. J Immunol 1999, 162:6572-6579.
33. + memory T cells. J Clin Invest 2003, 112:1444-1454.
34. Atamas SP, White B: InterleukinN4 in systemic sclerosis: not just an increase. Clin Diagn Lab Immunol 1999, 6:658-659.
35. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K: Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997, 24:328-332.
36. Postlethwaite AE, Holness MA, Katai H, Raghow R: Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 1992, 90:1479-1485.
37. + lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999, 42 1168-1178.
38. Sato S, Hasegawa M, Takehara K: Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001, 27:140-146.
39. Demeure CE, Yang LP, Byun DG, Ishihara H, Vezzio N, Delespesse G: Human naive CD4 T cells produce interleukin-4 at priming and acquire a Th2 phenotype upon repetitive stimulations in neutral conditions. Eur J Immunol 1995, 25:2722-2725.
40. Cohen SB, Webb LM, Feldmann M: The method of deriving human T-cell clones alters the proportion of IL-10-producing cells. Immunology 1996, 87:343-347.
41. Molteni M, Della Bella S, Mascagni B, Bazzi S, Zulian C, Compasso S, Lessi M, Score R: Increased interferon-gamma (IFN-γ) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud's phenomenon. Clin Exp Immunol 1999, 116:164-168.
42. Duncan M R, Berman B: Gamma interferon is the lymphokine and beta interferon the monokine responsible for inhibition of fibroblast collagen production and late but not early fibroblast proliferation. J Exp Med 1985, 162:516-527.
43. Yamane K, Ihn H, Asano Y, Jinnin M, Tamaki K: Antagonistic effects of TNF-α on TGF-β signaling through down-regulation of TGF-β receptor type II in human dermal fibroblasts. J Immunol 2003, 171 3855-3862.
44. Rekdal O, Osterud B, Svendsen JS, Winberg JO: Evidence for exclusive role of the p55 tumor necrosis factor (TNF) receptor in mediating the TNF-induced collagenase expression by human dermal fibroblasts. J Invest Dermatol 1996, 107:565-568.
45. Postlethwaite AE, Furst DE, Wong WK, Clements P: Oral tolerance (OT) induction to type I collagen (CI) significantly reduces the skin score in patients with diffuse systemic sclerosis (SSc) with late-phase disease. Results of a NIAMS/NIAID multicenter phase II placebo-controlled double blind clinical trial. Arthritis Rheum 2005, 52:4109-L28.